此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

皮质类固醇注射治疗膝骨关节炎的最佳麻醉剂 (Injections)

皮质类固醇注射治疗膝骨关节炎的最佳麻醉剂。

To evaluate pain relief from corticosteroid injection with and without anesthetic as well as with variable volume of anesthetic. Pain relief will be measured using the VAS pain score at the time of the injection as well as several time points following the injection to capture pain relief longevity. The investigators intend to evaluate how well the patients tolerate corticosteroid mixtures without anesthetic as well as with different volumes of anesthetic. Primary measure will be the time from procedure when postoperative status is considered success (as measured by global perceived improvement score).

研究概览

详细说明

Primary objective is to evaluate pain relief from corticosteroids, Kenalog without anesthetic as well as with different volumes of anesthetic. The investigators will measure the VAS pain score at the time of the injection as well as several time points following the injection. Additionally, the investigators will evaluate how long the injection provided pain relief for the patient.

The secondary intend is to evaluate how well the patients tolerate Kenalog mixtures without anesthetic as well as with different volumes of anesthetic by using the VAS pain scale.

The investigators hypothesize that patient with lower volume of injection will experience less pain during the procedure and that there will be no statistically significant difference in pain level between the study groups during the study period.

研究类型

介入性

注册 (实际的)

75

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Tampa、Florida、美国、33637
        • Florida Orthopaedic Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients must be 18 years of age and be able to consent for themselves.
  2. OA grade Kellgren Lawrence Stage II or III.
  3. Diagnosis of primary osteoarthritis.

Exclusion Criteria:

  1. Patients with other forms of arthritis such as inflammatory arthritis.
  2. History of narcotic use for the past 6 months.
  3. Kellgren Lawrence arthritis grade 1 or 4.
  4. Pregnant women and prisoners.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Kenalog with 0ml bupivacaine

The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0ml of bupivacaine. The patients will be randomized into this group.

Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.

其他名称:
  • 布比卡因
  • 凯那洛
  • 膝关节注射
  • 皮质类固醇注射液
实验性的:Kenalog with 4ml bupivacaine

The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,4ml of bupivacaine. The patients will be randomized into this group.

Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.

其他名称:
  • 布比卡因
  • 凯那洛
  • 膝关节注射
  • 皮质类固醇注射液
实验性的:Kenalog with 0.25% bupivacaine

The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0.25% of bupivacaine. The patients will be randomized into this group.

Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.

其他名称:
  • 布比卡因
  • 凯那洛
  • 膝关节注射
  • 皮质类固醇注射液

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Injection for Knee Pain
大体时间:Prior to procedure (in office)

Visual Analogue Scale (VAS)

Prior to procedure (in office)
Injection for Knee Pain
大体时间:Immediate post procedure (in office)

Visual Analogue Scale (VAS)

Immediate post procedure (in office)
Injection for Knee Pain
大体时间:2 minutes post procedure (in office)

Visual Analogue Scale (VAS)

2 minutes post procedure (in office)
Injection for Knee Pain
大体时间:Day 1 post procedure (phone interview)

Visual Analogue Scale (VAS)

Day 1 post procedure (phone interview)
Injection for Knee Pain
大体时间:Day 14 post procedure (through EDC)

Visual Analogue Scale (VAS)

Day 14 post procedure (through EDC)
Injection for Knee Pain
大体时间:Day 42 post procedure (in office)

Visual Analogue Scale (VAS)

Day 42 post procedure (in office)
Injection for Knee Pain
大体时间:Day 84 post procedure (through EDC)

Visual Analogue Scale (VAS)

Day 84 post procedure (through EDC)

次要结果测量

结果测量
措施说明
大体时间
Assessment of Knee Pain
大体时间:Immediate Post-op (in office)

Global Perceived Improvement

Immediate Post-op (in office)
Assessment of Knee Pain
大体时间:Day 1 post procedure (phone interview)

Global Perceived Improvement

Day 1 post procedure (phone interview)
Assessment of Knee Pain
大体时间:Day 42 post procedure (in office)

Global Perceived Improvement

Day 42 post procedure (in office)
Assessment of Knee Pain
大体时间:Day 84 post procedure (through EDC)

Global Perceived Improvement

Day 84 post procedure (through EDC)

其他结果措施

结果测量
措施说明
大体时间
Medications
大体时间:Prior to procedure (in office)

Review of Medications

Prior to procedure (in office)
Medications
大体时间:Day 1 post procedure (phone interview)

Review of Medications

Day 1 post procedure (phone interview)
Medications
大体时间:Day 14 post procedure (through EDC)

Review of Medications

Day 14 post procedure (through EDC)
Medications
大体时间:Day 42 post procedure (in office)

Review of Medications

Day 42 post procedure (in office)
Medications
大体时间:Day 84 post procedure (through EDC)

Review of Medications

Day 84 post procedure (through EDC)
Review of Adverse Events
大体时间:Immediate post procedure (in office)

Any issues with procedure

Immediate post procedure (in office)
Review of Adverse Events
大体时间:Day 1 post procedure (phone interview)

Any issues with procedure

Day 1 post procedure (phone interview)
Review of Adverse Events
大体时间:Day 42 post procedure (in office)

Any issues with procedure

Day 42 post procedure (in office)
Review of Adverse Events
大体时间:Day 84 post procedure (through EDC)

Any issues with procedure

Day 84 post procedure (through EDC)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月1日

初级完成 (实际的)

2025年6月1日

研究完成 (实际的)

2025年12月1日

研究注册日期

首次提交

2023年6月5日

首先提交符合 QC 标准的

2023年6月13日

首次发布 (实际的)

2023年6月15日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅